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Volume 57, Number 5S Abstracts 75SResults: Overall incidence of VTE was 7.4% and
increased with risk level: 0% in low risk patients, 3.5%
in moderate risk patients, 5.5% in high risk patients
and 8.3% in highest risk group. The difference between
highest and high risk patients was statistically signiﬁcant
(P ¼ .005). Incidence of acquired VTE accelerated in
the highest risk group according to cumulative risk
score, which was signiﬁcant in the 7-8 (8.4%; P ¼
.0217) and 8+ (11.5%; P ¼ .0015) cohorts. The four
risk levels were signiﬁcantly associated with development
of VTE during hospitalization. Clinician-entered scores
were within 1 point of the retrospectively calculated
score in 74% of cases. However, in 26% of cases there
was signiﬁcant disagreement by $2 points between the
scores. The clinician-entered score signiﬁcantly underes-
timated risk in 80% of these cases. In patients misclassi-
ﬁed from the highest risk group downwards, the risk of
VTE was higher (P ¼ .0007) than the physician score
predicted.
Conclusions: The VTE risk assessment score is valid
in the critically ill and supports the use of individualized
risk assessment upon admittance to the ICU.
Clinician entered scores signiﬁcantly diverge from
retrospectively calculated scores in one quarter of cases
and result in poor discrimination of VTE risk. Discrep-
ancies were usually the result of under-scoring.
The impact of misclassiﬁcation on thromboprophylaxis
prescribing regimen and incidence of VTE requires further
study.
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Objectives: The CEAP classiﬁcation (Clinical-
Etiology-Anatomy-Pathophysiology) is the golden stan-
dard for classiﬁcation of chronic venous disease (CVD)
today and is often used as part of local guidelines when
selecting patients for treatment within the national health-
care system. Many clinicians ﬁnd both CEAP and local
guidelines difﬁcult to apply in clinical reality, and patients
often seek a second opinion if they disagree with the exam-
ining doctor. The aim of this study was to evaluate the
reproducibility of the clinical class of CEAP when used in
a clinical situation where the decision for reimbursement
of treatment was made.
Methods: At a high-volume center in Stockholm,
an unselected series of 78 patients (106 limbs) withvaricose veins or CVD were examined by three inde-
pendent surgeons with regard to CEAP “C”. It was
also determined whether there was a medical indication
for treatment according to the local guidelines,
which would allow for treatment to be funded by
the Stockholm County. Pairwise comparison with
simple kappa was used to investigate the inter-observer
reproducibility.
Results: The simple kappa for “C” between all
observers was 0.55-0.68 (95% CI), where least agreement
was noted in class C3. Medical indication had a simple
kappa of 0.35-0.57 (95% CI).
Conclusions: There was a considerable discrepancy
between the surgeons assessing the clinical class of CVD
and even more so when deciding the medical indication
for treatment. This may be due to inherent difﬁculties in
the CEAP, lack of speciﬁc training, or the simultaneous
assessment of reimbursement that may inﬂuence the
grading of clinical class.
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Objectives: Differences in access to vascular care
remain unexplained for patients with lower extremity
PAD. We studied relationships between the quality of
medical care for patients with PAD and access to vascular
care.
Methods: We identiﬁed a cohort of 52,505 Medi-
care patients with pre-existing diabetes, PAD, and
foot ulceration who required hospitalization for foot
cellulitis. Across regions in the Dartmouth Atlas, we
determined the proportion of patients that received
appropriate, high quality medical care, deﬁned as (1)
hemoglobin A1C testing, (2) podiatric care, and (3)
non-invasive vascular testing, all within 1 year of
hospital admission. We assessed regional relationships
between quality of medical care and vascular care,
deﬁned as diagnostic/therapeutic vascular care for
CLI patients.
Results: Across the United States, only 36% of dia-
betic patients with PAD and tissue loss received all three
components of high quality medical care; 76% received
2 of 3 components. A non-invasive vascular study was
absent in 41%. Provision of high-quality medical care
varied across regions, from 4% of patients in Mason
City, Iowa to 58% of patients in Sun City, Arizona.
Regions most likely to provide high quality medical care
were 24% more likely to provide invasive vascular care
(P < .001; Fig).
Conclusions: Fewer than 4 out of 10 Medicare dia-
betics with PAD and tissue loss receive appropriate, high
quality medical care. Quality improvement efforts at
Fig.
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high quality medical care is an important determinant of
access to vascular care.
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Objectives: While cilostazol is commonly used as an
adjunct following peripheral vascular interventions (PVI),
its efﬁcacy remains uncertain. We assessed the effect of cil-
ostazol on outcomes following PVI using meta-analytic
techniques.Methods: We searched MEDLINE (1946-2012),
Cochrane CENTRAL (1996-2012), and trial registries
for studies comparing cilostazol in combination with
antiplatelet therapy to antiplatelet therapy alone
following PVI. Treatment effects were reported as
pooled risk/hazard ratios using random effects
models.
Results: Two randomized trials and four retrospec-
tive cohort studies met inclusion criteria (total n ¼
1,522). Across studies, mean age ranged from 66-76
years, the majority of patients were male (59-82%), and
mean follow-up ranged from 18-37 months. Pooled esti-
mates demonstrated that the addition of cilostazol was
associated with decreased restenosis (RR, 0.71; P <
.001; 95% CI, 0.60-0.84), improved amputation-free
survival (HR, 0.63; P ¼ .002; 95% CI, 0.47-0.85),
improved limb salvage (HR, 0.42; P < .001; 95% CI,
0.27-0.66), and improved freedom from target lesion
revascularization (TLR) (RR, 1.36; P < .001; 95% CI,
1.14-1.61) (Fig). There was no signiﬁcant reduction in
mortality among those receiving cilostazol (RR, 0.73; P ¼
.21; 95% CI, 0.45-1.19).
Conclusions: The addition of cilostazol to standard
therapy following PVI is associated with a reduced risk of
restenosis, amputation and TLR in our meta-analysis of
six studies. Consideration of cilostazol as a medical adjunct
after PVI is warranted, presuming these ﬁndings are
broadly generalizable.
